Drug Profile

Research programme: anticancer peptide therapeutics - Interprotein

Latest Information Update: 28 Nov 2021

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Interprotein Corporation
Class Peptides
Mechanism of Action HAVCR2 protein inhibitors; KIR receptor antagonists; NK cell lectin-like receptor subfamily C antagonists; Protein-protein interaction inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No
Available For Licensing Yes - Cancer

28 Nov 2021 No recent reports of development identified for research development in Cancer in Japan
30 Oct 2017 Research programme: anticancer peptide therapeutics - Interprotein is available for licensing as of 30 Oct 2017. http://www.interprotein.com/program.html
30 Oct 2017 Early research in Cancer in Japan (unspecified route)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com